Imugene (IMU) AGM 2024 summary

Opening remarks and agenda

• Meeting opened by the Executive Chairman, acknowledging traditional land owners and confirming quorum and constitution of the meeting.

• Hybrid AGM held in November 2024, enabling both in-person and virtual participation, with agenda adjusted for a scheduled fire drill.

Board and executive committee updates

• Board introduced, including Paul Hopper (Executive Chairman), Leslie Chong (CEO), and several non-executive directors with major pharma backgrounds; Dr. Jens Eckstein resigned after five years.

• Adrian Atkinson appointed as returning officer for the poll.

• Leadership team credited with bringing over 17 FDA-approved drugs to market.

Overview of voting outcomes

• Proxies representing over two billion shares (27% of capital) received.

• Remuneration report: 63% for, 36% against.

• Re-election of Leslie Russell as director: 82% for, 14.3% against.

• Ratification of share issue to Precision BioSciences: 95.6% for, 3.69% against.

• Granting of performance rights and restricted stock units to directors: support ranged from 57.53% to 68.36% in favor, with notable opposition on some resolutions.

• Poll closed; results to be announced to the ASX.